Home>>Signaling Pathways>> Chromatin/Epigenetics>> HIF>>TM6089

TM6089 Sale

目录号 : GC37801

TM6089 是一种独特的 PHD 抑制剂,可刺激 HIF 活性而不会产生铁螯合作用,诱导血管生成并对缺血器官发挥保护作用。 TM6089 局部施用可增强血管生成,并且口服施用在表达缺氧反应的报告载体的转基因大鼠中刺激 HIF 活性。

TM6089 Chemical Structure

Cas No.:863421-32-3

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥3,846.00
现货
5mg
¥3,497.00
现货
10mg
¥4,721.00
现货
25mg
¥7,553.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. Local administration of TM6089 enhances angiogenesis, and oral administration stimulates HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector[1].

[1]. Nangaku M, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2548-54.

Chemical Properties

Cas No. 863421-32-3 SDF
Canonical SMILES O=C1N(C(C(C(CSC2=NC=CC=C2)=O)=C(N1C)N)=O)C
分子式 C13H14N4O3S 分子量 306.34
溶解度 DMSO : 41.67 mg/mL (136.03 mM; ultrasonic and warming and heat to 60°C) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 3.2643 mL 16.3217 mL 32.6435 mL
5 mM 0.6529 mL 3.2643 mL 6.5287 mL
10 mM 0.3264 mL 1.6322 mL 3.2643 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia

Arterioscler Thromb Vasc Biol 2007 Dec;27(12):2548-54.PMID:17932321DOI:10.1161/ATVBAHA.107.148551

Objective: Hypoxia inducible factor (HIF) plays a pivotal role in the adaptation to ischemic conditions. Its activity is modulated by an oxygen-dependent hydroxylation of proline residues by prolyl hydroxylases (PHD). Methods and results: We discovered 2 unique compounds (TM6008 and TM6089), which inhibited PHD and stabilized HIF activity in vitro. Our docking simulation studies based on the 3-dimensional structure of human PHD2 disclosed that they preferentially bind to the active site of PHD. Whereas PHD inhibitors previously reported inhibit PHD activity via iron chelation, TM6089 does not share an iron chelating motif and is devoid of iron chelating activity. In vitro Matrigel assays and in vivo sponge assays demonstrated enhancement of angiogenesis by local administration of TM6008 and TM6089. Their oral administration stimulated HIF activity in various organs of transgenic rats expressing a hypoxia-responsive reporter vector. No acute toxicity was observed up to 2 weeks after a single oral dose of 2000 mg/kg for TM6008. Oral administration of TM6008 protected neurons in a model of cerebrovascular disease. The protection was associated with amelioration of apoptosis but independent of enhanced angiogenesis. Conclusions: The present study uncovered beneficial effects of novel PHD inhibitors preferentially binding to the active site of PHD.